This document is an excerpt from the EUR-Lex website
Document 62017TN0354
Case T-354/17: Action brought on 6 June 2017 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)
Case T-354/17: Action brought on 6 June 2017 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)
Case T-354/17: Action brought on 6 June 2017 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)
Information about publishing Official Journal not found, p. 41–41
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
31.7.2017 |
EN |
Official Journal of the European Union |
C 249/41 |
Action brought on 6 June 2017 — Genomic Health v EUIPO (ONCOTYPE DX GENOMIC PROSTATE SCORE)
(Case T-354/17)
(2017/C 249/55)
Language of the case: English
Parties
Applicant: Genomic Health, Inc. (Redwood City, California, United States) (represented by: A. Reid, Solicitor)
Defendant: European Union Intellectual Property Office (EUIPO)
Details of the proceedings before EUIPO
Trade mark at issue: EU word mark ‘ONCOTYPE DX GENOMIC PROSTATE SCORE’ — Application for registration No 15 214 257
Contested decision: Decision of the Fifth Board of Appeal of EUIPO of 14 February 2017 in Case R 1682/2016-5
Form of order sought
The applicant claims that the Court should:
|
— |
annul the contested decision; |
|
— |
order EUIPO to pay the Applicant’s costs of and occasioned by this appeal. |
Pleas in law
The Applicant submits that the Contested Decision is incorrect and constitutes an:
|
— |
Infringement of the general principles of equal treatment, good administration and legal certainty; |
|
— |
Infringement of Article 7(1)(b) in conjunction with Article 7(2) of Regulation No 207/2009; |
|
— |
Infringement of Article 7(1)(c) in conjunction with Article 7(2) of Regulation No. 207/2009. |